Business Wire

XPENG

10.3.2022 14:02:20 CET | Business Wire | Press release

Share
XPENG kicks off P5 smart EV sedan reservation in four European markets and opens XPENG Experience Store in the Netherlands

XPENG (the “Company”, NYSE: XPEV and HKEX: 9868), a leading smart mobility and technology company, today kicks off customer reservations of its third and latest production model on the market, the XPENG P5 smart EV sedan, simultaneously in Denmark, the Netherlands, Norway and Sweden. The move marks a major milestone in its European expansion plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005596/en/

XPENG today is also opening its first XPENG Experience Store in the Netherlands, its second branded showroom in Europe, following the opening of the Stockholm XPENG Experience Store in Sweden last month.

The XPENG P5 is the Company’s first model to be made available simultaneously in four European markets. The customer reservation process is fully-digitized, and accessible immediately in each of these four markets, both via the XPENG official websites in each country, and the XPENG mobile APP launched earlier this week.

“The XPENG P5’s arrival in four key European markets is a new demonstration of our commitment to Europe,” said Leon He, Vice President of XPENG. “Each new XPENG model achieves a new level of technology sophistication. The P5 brings a host of differentiated features to a new customer base in Europe, a market where we are building ourselves as a long-term player,” said Mr. He.

The XPENG P5 – Intelligence that moves you

The XPENG P5, a mid-size family sedan, is equipped with version 2.5 of XPENG’s in-house developed Advanced Driver Assistance System (XPILOT), and its intelligent in-car operating system - Xmart OS. The P5 combines the advanced level of driver assistance with superior passenger comfort and convenience. Through firmware over-the-air (OTA) upgrades, the P5 will bring new features and optimized functions to customers on a continuous basis.

The sleek aerodynamic profile of the P5 with a large panoramic canopy glass sunroof, neat fastback and unobtrusive ducktail gives it a driving range of 465 km WLTP, powered by a battery of 66 kWh capacity.

The Xmart OS provides comprehensive cockpit and interior function management, with a 12.3-inch LCD dashboard, a 15.6-inch FHD high resolution (1920 * 1080) large center display, in-car voice control capable of distinguishing between driver and passenger positions, and a library of in-car Apps to assist, inform, and entertain driver and passengers.

This intelligent cockpit management is integrated into the stylish interior fittings, with heated leatherette seats, the Xfreebreath intelligent air purification system and advanced surround sound system. Many vehicle functions can also be accessed via mobile phone remote control.

For added convenience, the P5 incorporates 26 storage compartments and a 450L large trunk, plus an additional 70L compartment underneath.

XPENG experience store starts operation in the Netherlands

Concurrently, XPENG is also opening its first experience store in the Westfield Mall of the Netherlands in Leidschendam, conveniently close to major conurbations such as Rotterdam and The Hague. As well as the XPENG P5, the XPENG smart sports sedan P7, and the prototype of its flying vehicle XPENG X2 are also on display in the Westfield Mall experience store, demonstrating the brand’s vision of future mobility and its spirit of exploration.

Customers can make online reservations for XPENG P5 from today. The test drive will be available in April 2022.

Two additional stores in the Netherlands will open later this year in collaboration with XPENG's local partner Emil Frey, and the Company plans to open more stores in major cities across the Netherlands over the next few years.

XPENG P5 Specs

Dimension

Length x Width x Height (mm)

4808mm / 1840mm / 1520mm

Wheelbase (mm)

2768mm

Seats

5

Curb Weight (kg)

1715Kg

Cargo Space

520 L

 

Performance

Type of Drive

Front-wheel drive

Battery Capacity (kWh)

66 kWh

WLTP Driving Range (km)

465 Km

 

XPILOT 2.5 (ADAS)

High-definition Millimeter Wave Radar

5

Ultrasonic Wave Sensors

12

Autonomous Driving Surround View Camera

4

Autonomous Driving High Perception Camera

9

XPILOT Safety

XPILOT Driving

XPILOT Parking

 

Xmart OS In-car Intelligent System

15.6" Central Touch Screen Display

12.3" HD Liquid Crystal Intelligent Instrument Panel

Mobile App Remote Control

"Hey XPENG" Voice Assistant

Firmware over-the-air software updates

 

Exterior

Lightsaber 3.0 LED Lights

Lightsaber 3.0 LED DRL

Panoramic Sunroof

215/55R18 Michelin Tyre

 

About XPENG

XPENG is a leading smart mobility company founded with a mission to explore and drive smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley and San Diego. In 2021, XPENG established its European headquarters in the Netherlands, and is expanding its presence in Sweden, Norway and Denmark. XPENG's smart EVs are manufactured at its fully-owned plant in Zhaoqing, Guangdong Province, China. For more information, please visit: www.heyxpeng.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye